Study of Lenvatinib in Patients With Advanced Cancer and Aberrations in FGF/FGFR Signaling
Status:
Withdrawn
Trial end date:
2021-06-01
Target enrollment:
Participant gender:
Summary
This is a two center, open label, non-randomized Phase II study of lenvatinib in adult
subjects with recurrent or refractory advanced cancers with aberration(s) in FGF/FGFR
signaling. Treatment will consist of daily oral administration of Lenvatinib in 28-day
cycles.